Drugs for Asthma and COPD Flashcards
1
Q
Albuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- risk of headache, dizziness, dry mouth, cough
2
Q
Terbutaline
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for treatment or prophylaxis of bronchospasm associated with asthma
- only available as SubQ
- risk of headache, nausea, tachycardia, and palpitations.
3
Q
Metaproterenol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for bronchial asthma and for reversible bronchospasm
- risk of CV effects, paradoxical bronchospasm
4
Q
Pirbuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- used for reversal of bronchospasm in pts 12 years or older
- risk of CV effects on pulse or BP
5
Q
Levalbuterol
A
- SABA (Short Acting β2 Agonist): reverses the bronchoconstriction of asthma by relaxing airway smooth muscle
- Used in treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.
6
Q
Beclomethasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 5 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- risk of adrenal dysfunction
7
Q
Budesonide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
8
Q
Ciclesonide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use for relief of acute bronchospasm
- less likely to cause candidiasis
9
Q
Flunisolide
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 6 years of age and older
- may replace oral CS
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
10
Q
Fluticasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 4 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- risk or oral candidiasis
11
Q
Mometasone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy in patients 4 years of age and older
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- do NOT use in pts with sensitivity to milk proteins, as treatment for status asthmaticus, or severe episodes of asthma
12
Q
Triamcinolone
A
- Inhaled corticosteroid
- Used as maintenance treatment for asthma and as prophylactic therapy
- reduce eosinophils in airway and sputum, and inhibit transcription of inflammatory proteins
- May replace Oral CS
- do NOT use as treatment for status asthmaticus, or severe episodes of asthma
- risk of adrenal dysfunction
13
Q
Prednisone
A
- Oral Corticosteroid
- Used as an anti-inflammatory or immunosuppressive agent and in endocrine conditions
- May lead to hypothalamic-pituitary-adrenal (HPA) axis suppression
14
Q
Fomoterol
A
- LABA (Long Acting β2 Agonist)
- Treatment of asthma in patients ≥5 years as an ADD-ON to a long-term asthma control medication such as an inhaled corticosteroid.
- Maintenance treatment of bronchoconstriction in patients with COPD
- risk of asthma-related deaths and asthma-related hospitalizations.
15
Q
Salmeterol
A
- LABA (Long Acting β2 Agonist)
- Treatment of asthma in patients aged 4 years and older. Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older.
- Also, maintenance treatment of bronchospasm associated with COPD